Abbott Laboratories Shares Drop After Revenue Miss and Lower Profit Forecast
Abbott Laboratories reported a revenue miss for the fourth quarter and issued soft profit guidance for early 2026. The company faces significant headwinds in its diagnostics segment.
Insights:
Abbott Laboratories shares fell 7% in premarket trading on Thursday after the healthcare giant reported fourth-quarter 2025 revenue that missed Wall Street expectations and provided a cautious outlook for the first quarter of 2026. The company, based in the US 
US, reported revenue of $11.46 billion for the final quarter of last year, falling short of the $11.80 billion analysts had projected. While adjusted earnings per share for the fourth quarter came in at $1.50, matching consensus estimates, the forward-looking guidance disappointed the market.
US, reported revenue of $11.46 billion for the final quarter of last year, falling short of the $11.80 billion analysts had projected. While adjusted earnings per share for the fourth quarter came in at $1.50, matching consensus estimates, the forward-looking guidance disappointed the market.For the first quarter of 2026, Abbott Laboratoriesexpects adjusted earnings between $1.12 and $1.18 per share, which is below the $1.20 per share analysts had anticipated. Chief Executive Officer robert ford stated that while the company is navigating near-term pressures, it remains well positioned for accelerating growth in 2026. The management team is banking on several new product launches to drive future performance and offset current challenges.
